Comparative studies of various hyaluronic acids produced by microbial fermentation for potential topical ophthalmic applications.
This work presents a comparative study of various hyaluronic acids (HA) produced by fermentation of either Bacillus subtilis or Streptococcus towards the selection of an optimal molecular weight (MW) HA for the preparation of topical ophthalmic formulations. The influence of HA MW on water binding capacity, sterile filtration, rheological properties, precorneal residence time and ocular tolerance of ophthalmic solutions was investigated. Molecular weight did not affect hydration of hyaluronic acid according to differential scanning calorimetry (DSC). In general, medium MW HA (0.6-1 MDa) resulted in solutions that were superior in terms of sterile filtration and kinematic viscosity requirements compared to high MW HA (>1 MDa). Moreover, all HA-based solutions exhibited well-defined viscoelastic properties that depend on MW. Gamma scintigraphic data indicated that HA MW at 0.1% concentration (w/v) and HA origin did not significantly affect the corneal residence time on rabbit eyes. A 0.3% solution of high MW HA had a prolonged residence time in the precorneal area compared to a medium MW HA at the same concentration. Finally, an in vivo ocular irritation test based on confocal laser scanning ophthalmoscopy (CLSO) conclusively showed the excellent tolerance of both Bacillus-derived HA and Streptococcus-derived HA after topical instillation onto the corneal surface. Overall, this comprehensive work highlights the superiority of medium MW hyaluronic acid for topical ophthalmic formulations based on their physico-chemical and biological properties, tolerance and handling. Such solutions are expected to enhance tear film stability, to allow for maximum comfort, and to exhibit high residence times, while being biocompatible and easy to sterile filter.
Novozymes Biopolymer A/S, Krogshoejvej 36, DK-2880 Bagsvaerd, Denmark. fagu@novozymes.com
Fanny
F
Guillaumie
Pascal
P
Furrer
Olivia
O
Felt-Baeyens
Birgit L
BL
Fuhlendorff
Søren
S
Nymand
Peter
P
Westh
Robert
R
Gurny
Khadija
K
Schwach-Abdellaoui
D000818:Animals; D001412:Bacillus subtilis / Q000737:chemistry / Q000378:metabolism; D001672:Biocompatible Materials / Q000737:chemistry / Q000378:metabolism; D004337:Drug Carriers / Q000737:chemistry / Q000378:metabolism / Q000627:therapeutic use; D015352:Dry Eye Syndromes / Q000188:drug therapy; D004548:Elasticity; D005128:Eye Diseases / Q000188:drug therapy; D005260:Female; D005285:Fermentation; D006801:Humans; D006820:Hyaluronic Acid / Q000737:chemistry* / Q000378:metabolism* / Q000627:therapeutic use; D008297:Male; D008422:Materials Testing; D008970:Molecular Weight; D009883:Ophthalmic Solutions / Q000737:chemistry* / Q000378:metabolism* / Q000627:therapeutic use; D011817:Rabbits; D012212:Rheology; D013291:Streptococcus / Q000737:chemistry / Q000378:metabolism; D014783:Viscosity
D001672:Biocompatible Materials; D004337:Drug Carriers; D009883:Ophthalmic Solutions; D006820:Hyaluronic Acid